Navigation Links
Arena Pharmaceuticals Obtains Equity Financing Commitment of Up to $50 Million
Date:3/23/2009

SAN DIEGO, March 23 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today it has obtained an equity financing commitment of up to $50 million from Azimuth Opportunity Ltd. During the 18-month term of the equity financing commitment, Arena may sell newly issued registered shares of its common stock to Azimuth Opportunity Ltd. at a pre-negotiated discount to the market price. Arena will determine, at its sole discretion, the timing and amount of any sales of its stock, subject to certain conditions. In no event may Arena sell more than 14,838,891 shares of its common stock under this arrangement with Azimuth Opportunity Ltd., which represents one share less than twenty percent of Arena's currently outstanding shares.

About Arena Pharmaceuticals

Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate, lorcaserin, is being investigated in a Phase 3 clinical trial program for the treatment of obesity. Arena's broad pipeline of novel compounds target G protein-coupled receptors, an important class of validated drug targets, and includes compounds being evaluated independently and with partners, including Merck & Co., Inc., and Ortho-McNeil-Janssen Pharmaceuticals, Inc.

Arena Pharmaceuticals(R) and Arena(R) are registered service marks of the company. "APD" is an abbreviation for Arena Pharmaceuticals Development.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Arena's financing plans, strategy, internal and pa
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Arena Pharmaceuticals to Present at the Bear Stearns 20th Annual Healthcare Conference
2. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
3. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
4. Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index
5. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Arena Pharmaceuticals to Report Third Quarter 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, October 17, 2007
7. Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results
8. Arena Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Arena Pharmaceuticals Appoints Phillip M. Schneider and Randall E. Woods to Board of Directors
10. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
11. Arena Pharmaceuticals Enters Into Strategic Agreements for the Manufacture of Pharmaceutical Material, Including Lorcaserin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2014)... HealthTronics, Inc. , a ... products and services, has signed a distribution agreement ... Corporation for its high precision laser technology. ... invasive, mobile, surgical technology—offering more choices for healthcare ... HealthTronics will make available Clinicon’s FDA-cleared SureLase™ CO2 ...
(Date:9/19/2014)... rather than electricity, to move data would consume ... a growing concern as chips, transistor counts rise. ... circuits light emitters, modulators, and detectors ... light source for optical chips is molybdenum disulfide ... as a single, atom-thick layer. Other experimental on-chip ...
(Date:9/19/2014)... , Sept. 19, 2014 Pfenex Inc. (NYSE ... development of high-value and difficult to manufacture proteins including ... at the 21 st Annual NewsMakers in the ... . Bertrand Liang , chief executive officer of ... programs and business strategy on Friday, September 26, 2014 ...
(Date:9/19/2014)... ROCKLAND, Massachusetts , September 19, 2014 ... with the 53rd European Society for Paediatric Endocrinology (ESPE) ... advancement of science and medical research in the field ... of Merck KGaA, Darmstadt, Germany , ... Growth Innovation (GGI) for 2014. The awards were announced ...
Breaking Biology Technology:HealthTronics Announces Distribution Agreement with Clinicon-Laser Surgical Device Expands Minimally Invasive, Mobile Technology Portfolio 2HealthTronics Announces Distribution Agreement with Clinicon-Laser Surgical Device Expands Minimally Invasive, Mobile Technology Portfolio 3Toward optical chips 2Toward optical chips 3Pfenex to Present at Upcoming Industry Conference on September 26 2EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 2EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 3
... (NPWH) Encourages Women to Get Informed and Ask ... growing awareness of HPV,(human papillomavirus), the primary cause of ... of Nurse Practitioners in Women,s,Health (NPWH) found that many ... prevent the disease. Despite the fact that there is ...
... Inc.,(Nasdaq: OSTE ), a leader in the emerging ... total revenue for the year,ending December 31, 2007 increased ... year ended December 31, 2006. Revenue from "core" product,lines, ... year,2007, an increase of 15% over core product revenue ...
... still flawed government-wide plan for nanotechnology risk research ... Federally-funded studies essential to managing possible risks from ... top-down strategy tied to projected commercialization, expected human ... , The National Nanotechnology Initiatives (NNI) ...
Cached Biology Technology:Survey Shows Most Women Can't Separate Fact From Fiction When It Comes to Cervical Cancer Prevention 2Survey Shows Most Women Can't Separate Fact From Fiction When It Comes to Cervical Cancer Prevention 3Survey Shows Most Women Can't Separate Fact From Fiction When It Comes to Cervical Cancer Prevention 4Osteotech Reports 2007 Full Year and Fourth Quarter Financial Results; Full Year Revenue of $104.3 Million Exceeds $100 Million Milestone; Diluted Earnings Per Share Was $.15 in 2007 2Osteotech Reports 2007 Full Year and Fourth Quarter Financial Results; Full Year Revenue of $104.3 Million Exceeds $100 Million Milestone; Diluted Earnings Per Share Was $.15 in 2007 3Osteotech Reports 2007 Full Year and Fourth Quarter Financial Results; Full Year Revenue of $104.3 Million Exceeds $100 Million Milestone; Diluted Earnings Per Share Was $.15 in 2007 4Osteotech Reports 2007 Full Year and Fourth Quarter Financial Results; Full Year Revenue of $104.3 Million Exceeds $100 Million Milestone; Diluted Earnings Per Share Was $.15 in 2007 5Osteotech Reports 2007 Full Year and Fourth Quarter Financial Results; Full Year Revenue of $104.3 Million Exceeds $100 Million Milestone; Diluted Earnings Per Share Was $.15 in 2007 6Federal nanotech risk research plan still comes up short 2
(Date:9/18/2014)... found clownfish larvae can swim up to 400 kilometres in ... cope with environmental change. , Clownfish spend their entire adult ... babies they must wander the open ocean, says study co-author, ... Coral Reef Studies (Coral CoE) at James Cook University. , ... now we,ve been given a rare glimpse into how far ...
(Date:9/17/2014)... UCLA atmospheric scientists were instrumental in the creation of ... tool to classify the fire threat potential of the ... a spark into an inferno. The index was introduced ... with UCLA and San Diego Gas and Electric. , ... to "extreme" that will be used to help fire ...
(Date:9/17/2014)... EC-FP5 four-year project, delivering its first release in 2004. ... in several EC projects, as a part of the ... BON), to increase the general awareness of the work ... dissemination of the Fauna Europaea results, the ... e-Publishing tools to prepare data papers for all 56 ...
Breaking Biology News(10 mins):Nemo's epic journey to find a new home 2UCLA scientists play key role in developing new Santa Ana Wildfire Threat Index 2Contributions on Fauna Europaea: Data papers as innovative model on expert involvement 2
... Leader, in One-Time Passwords for Highest Ability to Execute and ... RSA, The Security Division of EMC (NYSE: EMC ... An Overview and Competitive Analysis for the One Time ... in one-time password (OTP) technology for strong authentication based upon ...
... LA JOLLA, CA, June 19, 2009Researchers at The ... and Ohio State University have used a very sensitive ... to exist in one "natural" three-dimensional structure (shape), can ... the protein,s chemical environment. One folded form is active ...
... of nanomaterials with enhanced performance characteristics for use in ... people coming into direct contact with these materials. ... the market including clothes, skin lotions and cleaning ... and therapeutic nanocarriers have been designed for targeted drug ...
Cached Biology News:RSA Designated as the Leader in One-Time Password Market by Frost & Sullivan 2RSA Designated as the Leader in One-Time Password Market by Frost & Sullivan 3RSA Designated as the Leader in One-Time Password Market by Frost & Sullivan 4Researchers observe single protein dimers wavering between two symmetrically opposed structures 2Researchers observe single protein dimers wavering between two symmetrically opposed structures 3Researchers observe single protein dimers wavering between two symmetrically opposed structures 4Research explores interactions between nanomaterials, biological systems 2Research explores interactions between nanomaterials, biological systems 3Research explores interactions between nanomaterials, biological systems 4
... functional protein microarray is the first microarray ... interactions on a proteome scale. The Yeast ... frames (ORFs) expressed as 5'-GST fusions, purified ... inch x 3 inch nitrocellulose-coated slide. With ...
... Useful for the mechanical harvesting of cells ... ensures even contact with the growth surface ... 75cm flasks • Individually wrapped • Sterilized ... This CLS number is a new product ...
... description: Designed for use with dishes and ... is a new product number, created to ... no availability yet, please order under the ... service for assistance. Comp Dim: blade L ...
... combine the proven features of the pET, ... provides all of the benefits and versatility ... backbone. The pTriEx vectors have been extensively ... in all three expression systems. In each ...
Biology Products: